ArticleAmerican journal of obstetrics and gynecology2011
Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation.
Article in American journal of obstetrics and gynecology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- 17-Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta-analysis.BJOG : an international journal of obstetrics and gynaecology · 2016Pooled it
- Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?American journal of obstetrics and gynecology · 2015Trial
- Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.American journal of obstetrics and gynecology · 2014Trial
- Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation.American journal of obstetrics and gynecology · 2012Trial
- Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation.American journal of obstetrics and gynecology · 2012Trial
- What now? A critical evaluation of over 20 years of clinical and research experience with 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention.American journal of obstetrics & gynecology MFM · 2023Review
- Epigenetic Regulation of the Nitric Oxide Pathway, 17-α Hydroxyprogesterone Caproate, and Recurrent Preterm Birth.American journal of perinatology · 2018Article
- Pharmacokinetics of Hydroxyprogesterone Caproate and its Primary Metabolites during Pregnancy.AJP reports · 2018Article
- Development and usability of a new subcutaneous auto-injector device to administer hydroxyprogesterone caproate to reduce the risk of recurrent preterm birth.Medical devices (Auckland, N.Z.) · 2018Article
- Patient characteristics associated with 17-alpha hydroxyprogesterone caproate use among a high-risk cohort.American journal of obstetrics and gynecology · 2016Article
- Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats.Xenobiotica; the fate of foreign compounds in biological systems · 2016Article
- Basic obstetric pharmacology.Seminars in perinatology · 2014Review
- Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.Seminars in perinatology · 2014Review
- Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice.American journal of obstetrics and gynecology · 2013Review
- Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.Drug metabolism and disposition: the biological fate of chemicals · 2013Article
- Critical appraisal of the efficacy, safety, and patient acceptability of hydroxyprogesterone caproate injection to reduce the risk of preterm birth.Patient preference and adherence · 2013Article
- 17 α-Hydroxyprogesterone caproate (Makena™): in the prevention of preterm birth.Paediatric drugs · 2011Review
- Progesterone supplementation and the prevention of preterm birth.Reviews in obstetrics & gynecology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
objectiveThe purpose of this study was to define the pharmacokinetic parameters of 17-hydroxyprogesterone caproate (17-OHPC) in multifetal gestation. STUDY
designBlood was obtained at 24-28 weeks' gestation and at 32-35 weeks gestation in 97 women with twin and 26 women with triplet gestation who were receiving 17-OHPC. Six of the women with twins had daily blood sampling for 7 days between 24 and 28 weeks' gestation, and pharmacokinetic parameters were estimated with the use of noncompartmental analysis. Modeling was applied to estimate the population parameters and to simulate various treatment scenarios.
resultsThe apparent half-life of 17-OHPC was 10 days. Body mass index significantly impacted 17-OHPC concentrations, but fetal number and parity did not. Apparent clearance was significantly greater in African American than in white women (P = .025).
conclusionThis is the first pharmacokinetic analysis of 17-OHPC in pregnant women. Determination of half-life, covariates that affect plasma 17-OHPC concentrations, and the modeling of drug behavior provide insights into this drug's pharmacologic properties during multifetal pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.